Optimi Health (OPTI) AI Stock Analysis

• Market Cap: C$16.43M
• Dividend Yield: N/A
• Average Volume (3M): 67.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.12
• Revenue Growth: 89.28%
• EPS Growth: 18.45%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 42
• Industry: Agricultural Farm Products
• EPS (TTM): >-0.01
• Shares Outstanding: 96,638,170
• 10 Day Avg. Volume: 39,540
• 30 Day Avg. Volume: 67,139
• PEG Ratio: -0.34
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Optimi Health's overall score is primarily impacted by its financial challenges, including persistent losses and negative cash flows. While technical indicators and valuation metrics are weak, recent corporate events show potential for growth and market expansion, providing some positive outlook.

Optimi Health Business Overview & Revenue Model

Company Description

Optimi Health Corp. develops an integrated functional mushroom brand that focuses on the health and wellness food markets in Canada. The company also focuses on the cultivation, extraction, processing, and distribution of strains of functional mushroom. It offers a range of fungi varieties, which include Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. The company was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. Optimi Health Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Optimi Health generates revenue primarily through the cultivation and sale of functional mushrooms and psychedelic compounds. The company monetizes its operations via the production and distribution of health supplements derived from mushrooms, targeting both consumers and various health industries. Additionally, Optimi Health may engage in partnerships with research institutions and healthcare providers to develop psychedelic-assisted therapies, thereby creating potential revenue streams through collaborative agreements and licensing deals. The company's earnings are influenced by market demand for natural health products and the evolving regulatory landscape surrounding psychedelic substances.

Optimi Health Financial Statement Overview

Summary

Optimi Health shows potential with revenue growth and a strong equity position. However, persistent net losses, negative cash flows, and dependence on external financing highlight significant financial risks.

Income Statement

Optimi Health's revenue has shown growth from $0 in 2020 to $389,850 in 2024, indicating an upward trend. However, the company has consistently reported negative net income, with a significant net loss of $6,035,859 in 2024. The gross profit margin for 2024 is relatively healthy at 69.5%, but the absence of EBIT and negative EBITDA highlight challenges in operational efficiency.

Balance Sheet

The company maintains a high equity ratio, with stockholders’ equity consistently exceeding total liabilities, indicating financial stability. The debt-to-equity ratio is moderate at 0.29 in 2024, suggesting manageable leverage. However, the declining trend in total assets and stockholders' equity since 2021 should be monitored.

Cash Flow

Optimi Health's cash flow demonstrates a challenging picture with negative operating and free cash flows in all observed years, reflecting cash management issues. The operating cash flow to net income ratio is negative, underscoring cash flow inadequacy to cover net losses. Despite positive financing cash flows, reliance on external financing is evident.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	439.62K	389.85K	181.09K	80.72K	0.00	0.00
Gross Profit	-380.77K	270.91K	-157.04K	53.92K	-47.12K	-5.42K
EBITDA	-2.82M	-4.74M	-4.42M	-7.03M	-5.95M	-161.14K
Net Income	-4.33M	-6.04M	-5.19M	-7.38M	-6.04M	-169.22K
Balance Sheet
Total Assets	14.00M	14.55M	16.49M	16.82M	23.46M	6.17M
Cash, Cash Equivalents and Short-Term Investments	82.50K	103.66K	1.34M	1.89M	12.43M	4.47M
Total Debt	2.79M	2.75M	1.71M	157.58K	250.84K	156.32K
Total Liabilities	5.36M	4.98M	3.28M	797.66K	2.40M	882.66K
Stockholders Equity	8.64M	9.58M	13.21M	16.02M	21.07M	5.29M
Cash Flow
Free Cash Flow	-2.13M	-4.43M	-4.41M	-11.73M	-10.96M	-898.27K
Operating Cash Flow	-2.08M	-4.28M	-3.60M	-4.58M	-6.02M	-143.45K
Investing Cash Flow	-84.12K	-154.02K	-706.02K	-3.15M	-9.19M	-754.83K
Financing Cash Flow	1.90M	3.19M	3.76M	1.19M	19.18M	5.37M

Optimi Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NLH	65 Neutral	C$23.57M	20.45	4.53%	―	4.09%	―
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
OPTI	50 Neutral	C$16.43M	―	-48.35%	―	89.28%	18.45%
CWBHF		$15.04M	―	-78.03%	―	―	―
ROMJF		$20.54M	―	-2.68%	―	―	―
PHRRF		$32.32M	―	-76.00%	―	―	―
GSD		C$20.75M	―	-41.09%	―	―	―

Optimi Health Corporate Events

Optimi Health Completes Major MDMA Export to Australia for PTSD Treatment

Optimi Health has completed its largest export of MDMA capsules to Australia, aimed at treating PTSD under the country’s Authorised Prescriber Scheme. This shipment, in partnership with Mind Medicine Australia, includes 1,000 GMP-certified MDMA capsules and marks a significant development as the Australian Department of Veterans’ Affairs will fund MDMA-assisted therapy for veterans. This initiative reflects growing governmental recognition of psychedelic-assisted treatments for mental health, potentially enhancing Optimi’s industry positioning and expanding access to innovative therapies.

Optimi Health Secures U.S. FDA Registration for Psychedelic Drug Supply

Optimi Health Corp. has obtained U.S. FDA Drug Establishment Registration, marking a significant regulatory milestone that allows the company to supply GMP-certified MDMA and psilocybin to authorized entities in the United States. This recognition positions Optimi to participate in the U.S. pharmaceutical supply chain, a crucial step as the U.S. market represents a significant opportunity for psychedelic-assisted therapies. The registration enables Optimi to engage in FDA filings, supply U.S. distributors, and file Abbreviated New Drug Applications (ANDAs) for generic formulations, enhancing its industry positioning and potential impact on stakeholders.